Geometric Mean (GM) Value of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Specific Serum Antibody;GM Value of Post-Booster Dose SARS-CoV-2 Specific Serum Antibody;Number of Participants with Adverse Events of Special Interest (AESIs), Including Multisystem Inflammatory Syndrome in Children (MIS-C), Myocarditis and/or Pericarditis;Number of Participants with AEs Leading to Discontinuation From Study Post-Booster Dose Through the Last Day of Study Participation;Number of Participants with Medically-Attended AEs (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Serum Antibody Levels that Meet or Exceed the Threshold of Protection From COVID-19;Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs);Seroresponse Rate of Post-Booster Dose of Vaccine Recipients;Seroresponse Rate of Vaccine Recipients

Geometric Mean (GM) Value of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Specific Serum Antibody;GM Value of Post-Booster Dose SARS-CoV-2 Specific Serum Antibody;Number of Participants with Adverse Events of Special Interest (AESIs), Including Multisystem Inflammatory Syndrome in Children (MIS-C), Myocarditis and/or Pericarditis;Number of Participants with AEs Leading to Discontinuation From Study Post-Booster Dose Through the Last Day of Study Participation;Number of Participants with Medically-Attended AEs (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Serum Antibody Levels that Meet or Exceed the Threshold of Protection From COVID-19;Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs);Seroresponse Rate of Post-Booster Dose of Vaccine Recipients;Seroresponse Rate of Vaccine Recipients

Geometric Mean (GM) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Specific Serum Antibody;Number of Participants with Adverse Events of Special Interest (AESIs), Including Multisystem Inflammatory Syndrome in Children (MIS-C), Myocarditis and/or Pericarditis;Number of Participants with Medically-Attended AEs (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Serum Antibody Levels that Meet or Exceed the Threshold of Protection From COVID-19;Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs);Seroresponse Rate of Vaccine Recipients

Geometric Mean (GM) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Specific Serum Antibody;Number of Participants with Adverse Events of Special Interest (AESIs), Including Multisystem Inflammatory Syndrome in Children (MIS-C), Myocarditis and/or Pericarditis;Number of Participants with Medically-Attended AEs (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Serum Antibody Levels that Meet or Exceed the Threshold of Protection From COVID-19;Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs);Seroresponse Rate of Vaccine Recipients

Geometric Mean (GM) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Specific Serum Antibody;Number of Participants with Adverse Events of Special Interest (AESIs), Including Multisystem Inflammatory Syndrome in Children (MIS-C);Number of Participants with Medically-Attended AEs (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Serum Antibody Levels that Meet or Exceed the Threshold of Protection From COVID-19;Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs);Seroresponse Rate of Vaccine Recipients

Geometric Mean (GM) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Specific Serum Antibody;Number of Participants with Adverse Events of Special Interest (AESIs), Including Multisystem Inflammatory Syndrome in Children (MIS-C);Number of Participants with Medically-Attended AEs (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Serum Antibody Levels that Meet or Exceed the Threshold of Protection From COVID-19;Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs);Seroresponse Rate of Vaccine Recipients

Geometric Mean (GM) of SARS-CoV-2 Specific Neutralizing Antibody (nAb);Number of Participants with Adverse Events of Special Interest (AESIs), including Multisystem Inflammatory Syndrome in Children (MIS-C);Number of Participants with Medically-Attended AEs (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Serum Antibody (Ab) Levels that Meet or Exceed the Threshold of Protection from COVID-19;Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs);Seroresponse Rate of Vaccine Recipients

Geometric Mean (GM) of SARS-CoV-2 Specific Neutralizing Antibody (nAb);Number of Participants with Adverse Events of Special Interest (AESIs), including Multisystem Inflammatory Syndrome in Children (MIS-C);Number of Participants with Medically-Attended AEs (MAAEs);Number of Participants with Serious Adverse Events (SAEs);Number of Participants with Serum Antibody (Ab) Levels that Meet or Exceed the Threshold of Protection from COVID-19;Number of Participants with Solicited Local and Systemic Adverse Reactions (ARs);Number of Participants with Unsolicited Adverse Events (AEs);Seroresponse Rate of Vaccine Recipients